Title : Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

Pub. Date : 2017 Apr 1

PMID : 27978579






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Conclusions and Relevance: Dual targeting of the MEK and PI3K/AKT pathways downstream of KRAS by selumetinib plus MK-2206 did not improve overall survival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based chemotherapy had failed. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens